Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sky Clinical Research Network Group

Neither a doctor nor a teaching hospital

Research payments

$39,245,601

817 payments

Through program year 2025, Sky Clinical Research Network Group is reported as receiving $39,245,601 in research payments, across 817 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,113,461 322
2024 Research $7,079,617 191
2023 Research $7,996,030 153
2022 Research $7,113,853 84
2021 Research $5,580,813 44
2020 Research $1,125,942 15
2019 Research $235,885 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $30,810,109 332 payments
  2. Regeneron Pharmaceuticals, Inc. $2,459,053 208 payments
  3. Pfizer Inc. $1,928,549 128 payments
  4. Amgen Inc. $1,734,798 2 payments
  5. Genentech, Inc. $566,415 53 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $424,818 12 payments
  7. Merck Sharp & Dohme Corporation $368,298 2 payments
  8. AstraZeneca Pharmaceuticals LP $314,582 1 payment
  9. Hoffmann-La Roche Limited $216,579 11 payments
  10. Sumitomo Pharma America, Inc. $170,228 29 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $5,080,040 10 payments
  2. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $2,921,974 16 payments
  3. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $2,459,053 208 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $1,785,216 12 payments
  5. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $1,734,798 2 payments
  6. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $1,713,171 10 payments
  7. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $1,697,040 4 payments
  8. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities (Attain-Maintain) $1,648,432 8 payments
  9. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $1,158,358 9 payments
  10. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $1,146,203 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record